{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:05:59Z","timestamp":1789113959988,"version":"build-2803163510"},"reference-count":11,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Human monoclonal (MoAb) anti\u2010CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks. The dithiothreitol (DTT) treatment of reagent cells to destroy CD38, combined with phenotyping\/genotyping, has been used to address this interference. Due to anti\u2010CD38 activity in the patient's plasma, RBC units will be crossmatch incompatible and labeled crossmatch\u2010incompatible, necessitating communication with the ordering team regarding the safety of blood transfusion. The recombinant soluble CD38 (sCD38) antigen neutralizes the MoAb in a patient's plasma and can be used to perform crossmatches. Here, we describe our experience with sCD38 in RBC crossmatching.<\/jats:p>\n <\/jats:sec>\n \n Study Design and Method<\/jats:title>\n We began using sCD38 (Grifols) for RBC crossmatching in January 2026 (using 6\u2009\u03bcL of sCD38 per crossmatch) following completion of a validation study. Because of the known interference of sCD38 with the Duffy blood group system (by denaturation), its use was limited to RBC crossmatching. We use the DTT method for antibody screening tests.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 128 RBC crossmatches were performed for 49 patients on daratumumab. The sCD38 neutralized daratumumab in all crossmatching samples. Thus, all units were labeled crossmatch\u2010compatible, eliminating the need for provider communication. At the last follow\u2010up, with type and screen for these patients, no new alloantibody was detected.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Soluble CD38 neutralized the anti\u2010CD38 MoAb, enabling crossmatch\u2010compatible RBC units to be issued and obviating the need to notify the provider of apparent incompatibility.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/trf.70389","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:12:31Z","timestamp":1789110751000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of soluble\n CD38<\/scp>\n in blood crossmatching for patients on anti\u2010\n CD38<\/scp>\n therapy: A single\u2010center experience"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7353-3633","authenticated-orcid":false,"given":"Ayda","family":"Javanbakht","sequence":"first","affiliation":[{"name":"Department of Pathology University of Texas Southwestern Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1710-0212","authenticated-orcid":false,"given":"David","family":"Hanna","sequence":"additional","affiliation":[{"name":"Transfusion Services University of Texas Southwestern Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3711-5700","authenticated-orcid":false,"given":"Grishma Amatya","family":"Jaspau","sequence":"additional","affiliation":[{"name":"Transfusion Services University of Texas Southwestern Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-5158","authenticated-orcid":false,"given":"Ravi","family":"Sarode","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Texas Southwestern Dallas Texas USA"},{"name":"Department of Internal Medicine University of Texas Southwestern Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121632"},{"issue":"3","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.46989\/001c.141401","article-title":"Consensus guidelines and recommendations for the anti\u2010CD38\u2010based therapy in clinical practice for relapsed\/refractory multiple myeloma: from the pan\u2010Pacific multiple myeloma working group","volume":"7","author":"Chen W","year":"2025","journal-title":"Clin Hematol Int"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.08.001"},{"issue":"649441","key":"e_1_2_8_6_1","first-page":"1","article-title":"The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease","volume":"12","author":"Zaninoni AGJ","year":"2021","journal-title":"Front Immunol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1578-z"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13150"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15202"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13789"},{"issue":"3","key":"e_1_2_8_11_1","first-page":"180","article-title":"Multicenter evaluation of soluble CD38: neutralizing anti\u2010CD38 pan\u2010reactivity to enable alloantibody detection","volume":"24","author":"Engstr\u00f6m C","year":"2025","journal-title":"Blood Transfus"},{"key":"e_1_2_8_12_1","volume-title":"Novel recombinant CD38 for use in pretransfusion diagnostics","author":"Binda MFV","year":"2018"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.70389","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:12:32Z","timestamp":1789110752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.70389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":11,"alternative-id":["10.1111\/trf.70389"],"URL":"https:\/\/doi.org\/10.1111\/trf.70389","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2026-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"trf.70389"}}